Methotrexate pneumonitis precipitated by switching from oral to parenteral administration.
Collins
K
K
Rheumatology and General Medicine, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, UK.
Aspey
H
H
Todd
A
A
Saravanan
V
V
Rynne
M
M
Kelly
C
C
D000284:Administration, Oral; D000368:Aged; D001168:Arthritis / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007279:Injections, Subcutaneous; D002955:Leucovorin / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects*; D010102:Oxygen Inhalation Therapy; D011014:Pneumonia / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D002955:Leucovorin; D008727:Methotrexate